RAS pathway mutations were identified in 7.9% of patients, with 2.9% harboring mutations with a VAF ≥5%, consistent with a previous study that used a cutoff of 5% VAF.11 Likewise, the incidence of ATRX aberrations is consistent with previous reports.3,37 Only one tumor harbored a clonal TP53 mutation, a frequency lower than previous reports,11 which may be due to our strict filtering criteria. Here, ATRX is linked to neoplasm.